DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Sickle Cell Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.
DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Sickle Cell Disease Overview
Sickle cell disease (SCD) is a group of inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS) which encodes hemoglobin subunit β. HbS is inherited in an autosomal recessive way and can occur due to homozygosity for HbS (HbSS). HbS is functional and soluble when oxygenated, but upon deoxygenation, it polymerizes, leading to the generation of deformed red blood cells known as sickled cells and dense erythrocytes.
Sickle Cell Disease Symptoms
The Sickle Cell Disease symptoms include –
- Anemia
- Episodes of pain
- Swelling of hands and feet
- Frequent infections
- Delayed growth or puberty
- Vision problems
Some of the key facts of the Sickle Cell Disease Market Report:
- The Sickle Cell Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to a study published by Sedrak and Kondamudi, sickle cell anemia is the most common monogenic disorder
- It is estimated that in the United States, the population of sickle cell disease is approximately 100,000, and likely to increase
- As per a study by Wastnedge et al, the global meta-estimate for the birth prevalence of homozygous sickle cell disease was 111.91 per 100 ,000 live births, and that for heterozygous sickle cell disease was 4229.72 per 100 ,000
- Key Sickle Cell Disease Companies: Sanofi, Glycomimetics, Global Blood Therapeutics (GBT), CSL Behring, and others
- Key Sickle Cell Disease Therapies: GMI-1687, Inclacumab, CSL889, BIVV003, and others
- The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally
Get a Free sample for the Sickle Cell Disease Market Report
Key benefits of the Sickle Cell Disease Market report:
- Sickle Cell Disease market report covers a descriptive overview and comprehensive insight of the Sickle Cell Disease Epidemiology and Sickle Cell Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Sickle Cell Disease market report provides insights on the current and emerging therapies.
- Sickle Cell Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Sickle Cell Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Sickle Cell Disease market.
Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease market forecast
Sickle Cell Disease Epidemiology Segmentation:
The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Sickle Cell Disease
- Prevalent Cases of Sickle Cell Disease by severity
- Gender-specific Prevalence of Sickle Cell Disease
- Diagnosed Cases of Episodic and Chronic Sickle Cell Disease
Sickle Cell Disease Market
The dynamics of the Sickle Cell Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“Novel gene therapy candidates are being developed for the Sickle Cell Disease treatment include: CTX001(CRISPR Therapeutics/Vertex Pharma’s, and LentiGlobin BB305/Betibeglogene autotemcel (Bluebird Bio)”
Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiological Insights
Sickle Cell Disease Therapies
- GMI-1687
- Inclacumab
- CSL889
- BIVV003
Sickle Cell Disease Key Companies
- Sanofi
- Glycomimetics
- Global Blood Therapeutics (GBT)
- CSL Behring
Scope of the Sickle Cell Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Sickle Cell Disease Companies: Sanofi, Glycomimetics, Global Blood Therapeutics (GBT), CSL Behring, and others
- Key Sickle Cell Disease Therapies: GMI-1687, Inclacumab, CSL889, BIVV003, and others
- Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies
- Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Sickle Cell Disease Market Access and Reimbursement
Table of Contents
1. Sickle Cell Disease Market Report Introduction
2. Executive Summary for Sickle Cell Disease
3. SWOT analysis of Sickle Cell Disease
4. Sickle Cell Disease Patient Share (%) Overview at a Glance
5. Sickle Cell Disease Market Overview at a Glance
6. Sickle Cell Disease Disease Background and Overview
7. Sickle Cell Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Sickle Cell Disease
9. Sickle Cell Disease Current Treatment and Medical Practices
10. Sickle Cell Disease Unmet Needs
11. Sickle Cell Disease Emerging Therapies
12. Sickle Cell Disease Market Outlook
13. Country-Wise Sickle Cell Disease Market Analysis (2019–2032)
14. Sickle Cell Disease Market Access and Reimbursement of Therapies
15. Sickle Cell Disease Market drivers
16. Sickle Cell Disease Market barriers
17. Sickle Cell Disease Appendix
18. Sickle Cell Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Sickle Cell Disease treatment, visit @ Sickle Cell Disease Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
